{
    "nctId": "NCT01297231",
    "briefTitle": "Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI",
    "officialTitle": "Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI in Early Stage Breast Cancer Patients on Tamoxifen",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "To compare the level of BPE on breast MRI",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females with stage 0-3 breast cancer who have had or are planned to have a breast MRI within 1 year prior to starting tamoxifen\n* Premenopausal status is defined as intact ovaries and still menstruating\n* Clinical and MRI follow-up planned at MSKCC or MCKCC regional facility\n* Willing and able to undergo all study procedures\n\nExclusion Criteria:\n\n* Contraindication to breast MRI (such as non-compatible cardiac pacemakers or intracranial vascular clips, allergy to Gadolinium)\n* Bilateral breast cancer or treatment such as:\n* History of or planned bilateral breast irradiation\n* History of or planned bilateral mastectomy\n* Bilateral breast cancer\n* History of unilateral mastectomy or radiation treatment with contralateral breast cancer\n* Taking chemo- or hormonal therapy at the time of the baseline breast MRI\n* Estrogen and progesterone receptor negative breast cancer\n* GFR less than GFR \\< 30 mL/min/1.73m2\n* Postmenopausal women\n* Pregnant and/or nursing women\n* Less than 21 years of age",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}